Arbutus Secures Up to $2.25 Billion from Moderna Patent Settlement, Plans Shareholder Capital Return

summarizeSummary

Arbutus Biopharma has reached a major patent settlement with Moderna for up to $2.25 billion, significantly boosting its financial position and leading to a planned return of capital to shareholders. The company also continues its patent litigation against Pfizer/BioNTech with a favorable ruling.

check_boxKey Events

• Moderna Patent Litigation Settlement

  Arbutus and Genevant will receive an aggregate noncontingent lump sum payment of $950 million by July 8, 2026, with Arbutus entitled to 20% after litigation costs, plus its 16% equity ownership in Genevant. An additional contingent payment of up to $1.3 billion is possible based on a favorable ruling in the Moderna §1498 Appeal.

• Potential Shareholder Capital Return

  The company is evaluating a return of capital to shareholders in the third quarter of calendar year 2026, following the receipt of its portion of the noncontingent settlement payment.

• Ongoing Pfizer/BioNTech Patent Litigation

  The patent infringement lawsuit against Pfizer/BioNTech is ongoing, with a favorable claim construction ruling issued in September 2025, and further scheduling awaited.

• Strategic Restructuring and Cost Reduction

  During 2024 and 2025, Arbutus implemented significant workforce reductions and ceased discovery efforts, resulting in $12.9 million in restructuring charges in 2025 and a substantial reduction in net cash burn.

auto_awesomeAnalysis

Arbutus Biopharma has announced a transformative settlement with Moderna, Inc. and its affiliates, resolving all patent infringement litigation. This agreement includes a substantial noncontingent lump sum payment of $950 million (aggregate to Arbutus and Genevant) due by July 8, 2026, with Arbutus directly entitled to 20% of this amount after litigation costs, in addition to its 16% equity stake in Genevant. Furthermore, a contingent payment of up to $1.3 billion is possible based on the outcome of a limited appeal. This significant financial influx, representing a substantial portion of the company's market capitalization, is expected to dramatically improve Arbutus's liquidity and financial runway. The company is actively evaluating a return of capital to shareholders in Q3 2026, signaling a direct benefit to investors. Concurrently, Arbutus continues its patent infringement lawsuit against Pfizer/BioNTech, which saw a favorable claim construction ruling in September 2025, indicating further potential upside. These developments, alongside a strategic restructuring that reduced cash burn, position Arbutus with enhanced financial flexibility and a clearer path forward for its clinical programs, despite an FDA clinical hold on its AB-101 program in the U.S.